Aeglea BioTherapeutics Presents Additional Data from PEACE P

AUSTIN, Texas, April 11, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new ...

Related Keywords

Texas , United States , Aeglea Biotherapeutics , Deric Bradford , Anthonyg Quinn , Society For Inherited Metabolic Disorders , Drug Administration , Prnewswire Aeglea Biotherapeutics Inc , Nasdaq , Exchange Commission , European Medicines Agency , Aeglea Biotherapeutics Inc , Laboratory Measure , Inherited Metabolic Disorders , Annual Meeting , Patient Level Outcomes , Gross Motor Function Classification System , Score Range , Additional Secondary Efficacy Endpoints , Baseline Relative , About Pegzilarginase , Rare Pediatric Disease , Breakthrough Therapy , Fast Track , Orphan Drug , Orphan Drug Designation , European Medicines , Forward Looking , Securities Litigation Reform Act , Annual Report ,